PatientsVille.com Logo


Actos Medical Research Studies

Up-to-date List of Actos Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Actos Medical Research Studies

Rank Status Study
1 Unknown  Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
Conditions: Brain Neoplasms, Malignant;   Brain Neoplasms, Benign;   Malignant Meningioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma
Interventions: Drug: pioglitazone;   Drug: Pioglitazone
Outcome Measures: Best tolerated dose of 2 different doses of orally administered pioglitazone;   Toxicities associated with both dose levels;   To evaluate the effect of pioglitazone on glycemic levels and hemoglobin A1c values when pioglitazone is used as a cytoprotective agent concurrent with radiotherapy in normoglycemic patients.
2 Recruiting The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis
Condition: Hepatitis
Interventions: Drug: Pioglitazone;   Drug: placebo
Outcome Measures: Comparison between Pioglitazone and placebo groups in terms of steatosis and liver function tests;   Evaluation of clinical safety of Pioglitazone;   Comparison between Pioglitazone and placebo groups in terms of liver necroinflammation and fibrosis.
3 Recruiting Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
Condition: Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions: Drug: Pioglitazone;   Drug: Pioglitazone placebo
Outcome Measures: Time to diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD) for biomarker risk algorithm qualification;   Time to diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD) for pioglitazone-treated, non-Hispanic/Latino Caucasian subjects versus placebo-treated non-Hispanic/Latino, Caucasian subjects in the high-risk stratum.;   Change from baseline in cognitive decline on composite score on the cognitive test battery;   Change from baseline in instrumental activities of daily living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI])
4 Not yet recruiting Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy
Condition: Type II Diabetes Mellitus
Interventions: Drug: Pioglitazone;   Drug: Metformin;   Drug: Sulfonylurea
Outcome Measures: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24;   Change From Baseline in Fasting Plasma Glucose at Week 24
5 Recruiting Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
Conditions: Severe Sepsis;   Septic Shock
Intervention: Drug: Pioglitazone hydrochloride
Outcome Measures: Evaluate the pharmacokinetic and safety profile of pioglitazone in patients with severe sepsis and septic shock;   Examine the effect of pioglitazone treatment on inflammatory biomarkers of sepsis in patients with severe sepsis and septic shock
6 Recruiting Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
Condition: Nonalcoholic Steatohapatitis
Interventions: Drug: Roflumilast;   Drug: Pioglitazone;   Drug: Placebo
Outcome Measures: Percent Change from Baseline in Serum Alanine Transaminase (ALT);   Percent Change from Baseline in Serum Aspartate Transaminase (AST);   Change from Baseline in Liver Fat Content at 4 Months
7 Recruiting Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"
Condition: Bladder Cancer
Intervention: Drug: Pioglitazone
Outcome Measure: Bladder cancer rate
8 Unknown  Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)
Condition: Metabolic Parameters and Liver Histology
Interventions: Drug: Pioglitazone;   Drug: Pentoxifylline
Outcome Measures: Improvement in metabolic profile and histology;   Side effects
9 Not yet recruiting Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS
Conditions: Polycystic Ovary Syndrome;   Infertility
Interventions: Drug: induction of ovulation using letrozole-pioglitazone-metformin;   Drug: induction of ovulation using clomiphene citrate-pioglitazone-metformin;   Radiation: transvaginal ultrasound;   Other: body mass index (BMI) calculation;   Other: day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone;   Other: pretreatment blood urea and serum creatinine;   Other: serum estradiol (E2) on day 12;   Other: serum progesterone on day 21;   Other: blood urea and serum creatinine every month
Outcome Measures: ovulation rate;   number of follicles>18mm.;   endometrial thickness;   pregnancy rate
10 Unknown  Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD
Condition: ESRD
Intervention: Drug: Pioglitazone
Outcome Measures: Body composition;   Insulin sensitivity;   Protein metabolism
11 Unknown  Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
Conditions: Cystic Fibrosis;   Anti Inflammatory Non-Steroidal;   Neutrophils
Interventions: Drug: Pioglitazone;   Drug: Simvastatin;   Drug: Ibuprofen
Outcome Measure: Neutrophil delivery to the oral mucosa using a noninvasive mouth wash technique
12 Recruiting Pioglitazone for the Treatment of Insulin-Resistant and Bipolar Depression
Conditions: Bipolar Disorder;   Insulin Resistance
Interventions: Drug: Pioglitazone;   Drug: Placebo
Outcome Measures: Change in IDS-C30 total score;   Change in insulin resistance as quantified by homeostatic model assessment for insulin resistance (HOMA-IR);   Change in fasting lipid profile
13 Recruiting Pioglitazone Decreases Visceral Fat Metabolism
Condition: To Evaluate the Effect of Pioglitazone on Glucose Metabolism of Fat Tissue by Using FDG-PET/CT Imaging
Intervention: Drug: Pioglitazone vs Glimepiride
Outcome Measures: Effect of treatment on the nominal change in FDG uptake of fat tissue from baseline after 16 weeks of treatment as measured by FDG-PET/CT imaging.;   Change from baseline in plasma glucose/insulin homeostatic parameters and circulating inflammatory markers
14 Recruiting Pioglitazone for Lung Cancer Chemoprevention
Conditions: Lung Cancer;   Endobronchial Dysplasia
Interventions: Procedure: fluorescence bronchoscopy;   Procedure: quantitative high resolution CT scan;   Drug: PIOGLITAZONE VS. PLACEBO 30 mg
Outcome Measure: Changes in endobronchial histology
15 Not yet recruiting Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease
Conditions: LVM;   Type 2 Diabetic Patients With IHD;   Endothelial Function
Interventions: Drug: pioglitazone group;   Drug: Metformin group
Outcome Measures: The changes of LVM;   The changes of endothelial function
16 Recruiting Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity
Condition: Metabolic Syndrome
Interventions: Drug: Pioglitazone;   Drug: sugar pill
Outcome Measures: Sympathetic nervous system activity, measured as muscle sympathetic nervous activity and whole-body noradrenaline spillover;   Baroreflex function, adrenoceptor expression
17 Recruiting Pioglitazone in Follicular or Follicular Variant of Papillary Thyroid Cancers
Conditions: Follicular Thyroid Carcinoma;   Follicular Variant of Papillary Thyroid Carcinoma
Intervention: Drug: Pioglitazone
Outcome Measures: Tumor response;   Decrease in serum thyroglobulin;   Toxicity
18 Recruiting Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
Condition: Opioid Abuse
Intervention: Drug: pioglitazone
Outcome Measures: Subjective ratings of drug, mood, and physiological effects;   Analgesic responses using the cold pressor test
19 Unknown  PIoglitazone for PrEvention of Restenosis in Diabetic Patients
Conditions: Coronary Atherosclerosis;   Coronary Restenosis;   Diabetes
Interventions: Drug: Pioglitazone;   Drug: Placebo
Outcome Measures: In-Segment Late Loss;   Binary restenosis;   MACE;   Stent thrombosis
20 Unknown  Pioglitazone in Hepatitis C
Condition: Chronic Hepatitis C
Intervention: Drug: Pioglitazone
Outcome Measure:

These studies may lead to new treatments and are adding insight into Actos etiology and treatment.

A major focus of Actos research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Actos